For most cancer surgeries, there’s no ICU stay at all, or just one to two days when it is needed. Whether you go to the ICU depends on how major the operation is, your overall health and how smoothly the surgery goes. Smaller or minimally invasive procedures usually skip it entirely, while major chest or abdominal surgeries may need a short, planned stay for close monitoring.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “Patients often dread the ICU, but for most of my cases it’s either not needed or it’s a single night of close watching, not the long ordeal people imagine.”

ICU isn’t routine after cancer surgery, it’s reserved for specific situations. These are the factors that decide it.

• Size of the surgery: Major operations on the chest, abdomen or several organs at once are the cases most likely to need a planned ICU stay for safe monitoring.
• Your overall health: Existing heart, lung or kidney conditions often mean closer post-operative watching, even when the operation itself is only moderate in scale.
• How the surgery went: Heavy blood loss or a longer, more complex procedure than expected can call for a short ICU stay until the patient is stable.
• The surgical approach: Minimally invasive and robotic methods stress the body far less, which frequently removes the need for any ICU stay at all.

So the ICU is a precaution for some, not a routine for all. For a sense of how operation length plays in, our blog on breast cancer surgery covers timing in detail.

When the ICU is needed, the stay is normally short and planned in advance. These are the typical patterns patients see.

• Often none at all: A large share of cancer surgeries skip the ICU completely, with patients recovering on a regular ward from the very first day.
• One to two days: Where monitoring is genuinely needed, a day or two in intensive care is the usual length before moving to a normal room.
• Longer for major cases: Big chest or abdominal operations, or procedures like HIPEC, may need several days of intensive care to recover safely.
• Shorter with robotics: Less invasive surgery generally means a much shorter stay, or none, simply because the body has far less to recover from.

So even when the ICU is part of the plan, it’s usually brief. In suitable cases, robotic cancer surgery keeps that stay as short as possible by being gentler on the body.

Dr. Sandeep Nayak brings 24 years of surgical oncology experience, DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco-Surgery to surgery across all cancer types. He plans recovery as carefully as the operation itself, choosing approaches that keep ICU time and hospital stays as short as is safe.

That planning is what makes recovery smoother and far less frightening. Every case at MACS Clinic goes through a full tumour board, where the surgical and recovery plan is set before anything begins. Call +91 8104310753 to book your consultation.

References:

1. National Cancer Institute — Surgery to Treat Cancer. https://www.cancer.gov/
2. World Health Organisation — Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer

Grade 3 means the cancer cells look very different from normal cells under the microscope and tend to grow and divide faster. It describes the cancer’s behaviour, not how far it has spread, which is what the stage tells you. A higher grade often calls for more active treatment, but it doesn’t decide the outcome on its own. Many grade 3 cancers are still very treatable, especially when caught early.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “Grade 3 tells me the cancer is likely to move quickly, so I treat it promptly, but I always remind patients it’s one piece of the picture, not a verdict on how things will turn out.”

Grade is about how the cells look and behave, not how far they’ve travelled. Here’s what it signals.

• Very abnormal cells: Under the microscope these cells have lost their normal structure, and that disorganised look is what earns the grade 3 label.
• Faster growth: Cells this abnormal tend to divide quickly, so a grade 3 cancer usually grows more rapidly than a lower grade.
• Not the same as stage: Grade describes the cells themselves, while stage measures spread, so a grade 3 cancer can still be early stage.
• Guides the urgency: It tells the team to act promptly and often more intensively, which is exactly why it’s noted on the report.

So grade 3 describes pace, not destiny. For the bigger picture of where this finding comes from, our blog on a biopsy explains the process behind the report.

A higher grade usually shifts the plan toward acting faster and harder. These are the main ways.

• Prompt action: Because it grows quickly, treatment tends to start without unnecessary delay once the diagnosis is confirmed.
• Often more intensive: Grade 3 cancers may call for chemotherapy or radiation alongside surgery, rather than surgery alone.
• Surgery stays key: Removing the tumour remains central, with the higher grade shaping what’s added before or after it.
• Closer follow-up: Faster-growing cancers are watched more carefully afterward, so any change is picked up early.

So a grade 3 result means a more active plan, not a lost cause. When surgery leads that plan, robotic cancer surgery can remove the tumour precisely while keeping recovery short.

Dr. Sandeep Nayak brings 24 years of surgical oncology experience, DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco-Surgery to the treatment of every grade and type of cancer. He reads a grade 3 result in full context, against the stage, the scans and the cell type, rather than letting the number alone dictate the plan.

That balanced reading is what keeps treatment firm but not excessive. Every case at MACS Clinic goes through a full tumour board, where pathology, imaging and oncology weigh in together before anything is confirmed. Call +91 8104310753 to book your consultation.

References:

1. National Cancer Institute — Tumor Grade. https://www.cancer.gov/
2. World Health Organisation — Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer

HER2 positive means the cancer makes too much of a protein called HER2, which pushes it to grow and spread faster. It used to be worrying news, but it now opens the door to targeted drugs like trastuzumab that lock onto HER2 and work alongside chemotherapy and surgery. So while these cancers are more aggressive by nature, they’re also among the most treatable today thanks to that targeted approach.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “Twenty years ago HER2 positive was bad news, today it’s almost the opposite, because we have drugs that target it directly, so I treat that result as an opportunity, not a setback.”

The result points to how the cancer behaves and, more importantly, how to fight it. Here’s what it signals.

• Extra HER2 protein: The cancer cells carry far too much of this growth signal, which is what drives them to multiply more quickly than usual.
• More aggressive type: Left untreated it tends to grow and spread faster, so it’s taken seriously and treated promptly once confirmed.
• A clear target: That same protein is its weak spot, since targeted drugs can lock onto HER2 in a way that spares healthy cells.
• Confirmed by testing: The status comes from lab testing on the tumour, and a borderline result is double-checked before treatment is set.

So the label tells you both the threat and the route to beat it. The status itself comes from an IHC test, which reads exactly this kind of marker on the tumour.

A positive result reshapes the plan in a good way, adding tools that wouldn’t otherwise apply. These are the main shifts.

• Targeted therapy added: Drugs like trastuzumab go straight after the HER2 protein, and they’ve transformed outcomes for these cancers.
• Chemo works with it: Targeted therapy usually pairs with chemotherapy, the two together hitting the cancer harder than either alone.
• Surgery still matters: Removing the tumour stays central, with the targeted drugs working before or after to clear what’s left.
• Closer monitoring: Because these cancers move faster, follow-up tends to be tighter to catch any change early.

So HER2 positive today means more weapons, not fewer. When surgery is part of that plan, robotic cancer surgery can remove the tumour precisely while recovery stays short.

Dr. Sandeep Nayak brings 24 years of surgical oncology experience, DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco-Surgery to the treatment of HER2 positive and all other cancer types. He builds the surgery around the full molecular picture, so a marker like HER2 shapes the plan from the very start rather than later.

That joined-up approach is what gives targeted treatment its best footing. Every case at MACS Clinic goes through a full tumour board, where pathology, oncology and imaging weigh in together before anything is confirmed. Call +91 8104310753 to book your consultation.

References:

1. National Cancer Institute — HER2 and Cancer. https://www.cancer.gov/
2. World Health Organisation — Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer

Start with a few key parts and the report stops looking like a wall of jargon. The diagnosis line tells you whether the tissue is benign or malignant. The type and grade describe what the cancer is and how aggressive it looks. Margin status says whether it was fully removed. These sections carry the real meaning, though your doctor should always be the one to interpret them for your case.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “Patients should understand their own report, but I always warn them that one scary word out of context can cause needless panic, so read it to ask better questions, not to self-diagnose.”

A biopsy report follows a pattern once you know where to look. These are the sections that matter most.

• The diagnosis: This is the headline, telling you plainly whether the tissue is benign, malignant or needs more testing before anyone’s sure.
• Type and grade: Type names the cancer, while grade rates how abnormal the cells look, which hints at how fast it might grow.
• Margins: When tissue is removed, this says whether cancer reaches the cut edge, and a clear margin is exactly what you want to see.
• Extra markers: Hormone receptors, HER2 or similar findings appear here, and they often steer what treatment comes next.

So the report is really a few key answers wrapped in technical language. For the bigger picture of where it comes from, our blog on a biopsy explains the process behind it.

A handful of words trip people up and spark worry they don’t need to. Here’s what they actually mean.

• “Atypical”: It sounds alarming but often isn’t cancer, just cells that look unusual and may need a closer second look.
• “In situ”: This means the cancer is still contained where it started and hasn’t spread, which is generally an early, favourable finding.
• “Poorly differentiated”: It describes cells that look very abnormal, which can mean faster growth, but it’s only one piece of the full picture.
• “Positive margin”: This flags cancer at the edge of removed tissue, sometimes meaning a bit more surgery, not that anything has gone wrong.

So a frightening term rarely tells the whole story on its own. For tailored options, robotic cancer surgery is one path a clear report can point toward.

Dr. Sandeep Nayak brings 24 years of surgical oncology experience, DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco-Surgery to reading and acting on biopsy reports across all cancer types. He walks patients through their report line by line, turning intimidating terminology into something they can actually understand.

That plain explanation is what replaces fear with a clear next step. Every case at MACS Clinic goes through a full tumour board, where pathology, imaging and oncology weigh in together before anything is confirmed. Call +91 8104310753 to book your consultation.

References:

1. National Cancer Institute — Understanding Your Pathology Report. https://www.cancer.gov/
2. World Health Organisation — Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer

Not for everyone, but for certain cancers it genuinely matters. Genetic testing looks for inherited gene changes, like BRCA in breast and ovarian cancer, that can change how much tissue a surgeon should remove and whether the other side needs attention too. For most cancers it isn’t required, yet where a known gene is involved, the result can reshape the whole surgical plan. That’s why it’s considered case by case.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “When a patient carries a gene like BRCA, I plan the surgery differently, sometimes far more extensively, so I’d rather know before I operate than discover it afterwards.”

It isn’t routine for every patient, but in some situations it really earns its place. Here’s when.

• A strong family history: Several close relatives with the same cancer is a red flag that an inherited gene may be in play, and that’s worth checking first.
• Young at diagnosis: Cancer showing up unusually early often points to a genetic cause, which can change how the surgery is approached.
• Specific cancers: Breast, ovarian and colorectal cancers have well-known gene links, so testing here can directly affect the operation chosen.
• It changes the plan: If a result would mean removing more tissue or operating on both sides, knowing beforehand beats finding out later.

So testing first is about operating with the full picture. Much like what an IHC test adds at the cell level, a gene result fills in detail the surgeon needs before deciding.

When a gene shows up, it can shift the plan in real, practical ways. These are the main ones.

• Wider removal: A BRCA result in breast cancer, for instance, may steer a patient toward removing more tissue rather than a smaller operation.
• Both sides considered: Some inherited risks raise the odds for the other breast or ovary, so surgery may be planned to cover both.
• Timing other organs: A strong gene result sometimes brings forward preventive surgery on organs not yet affected.
• Family gets warning: A positive result flags risk for close relatives too, letting them screen early long before anything shows.

So the gene doesn’t just inform your surgery, it can protect your family. For suitable cases, robotic cancer surgery then carries out that tailored plan with precision.

Dr. Sandeep Nayak brings 24 years of surgical oncology experience, DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco-Surgery to surgery across all cancer types. He factors genetic results into the surgical plan from the start, rather than treating them as an afterthought once the operation is already decided.

That forward planning is what makes a surgery fit the patient, not just the tumour. Every case at MACS Clinic goes through a full tumour board, where genetics, pathology and imaging are weighed together before anything is confirmed. Call +91 8104310753 to book your consultation.

References:

1. National Cancer Institute — Genetic Testing for Cancer. https://www.cancer.gov/
2. World Health Organisation — Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer

Whether chemotherapy comes first (neoadjuvant) or surgery comes first (adjuvant) depends entirely on the tumour size, cancer type and stage. A multidisciplinary tumour board makes this call, weighing how best to achieve a complete cure, shrink the tumour to allow less invasive surgery, or lower the risk of the cancer coming back. So the order is picked to fit your case, not by some fixed rule.

According to Prof. Dr. Sandeep Nayak, Surgical Oncologist in India, “I’d never decide the order alone or out of habit, because for some cancers chemo first changes what surgery can actually achieve, and getting that sequence right matters as much as the operation itself.”

Sometimes it makes more sense to treat the body before touching the tumour. Here’s when.

• To shrink it down: A big or awkwardly placed tumour often softens up with chemo first, which makes it smaller and a lot easier to take out cleanly.
• To catch hidden spread: If there’s a real chance stray cells have slipped out, chemo upfront goes after them before surgery handles the main lump.
• To see how it responds: Chemo first shows how the tumour reacts to the drugs, and that tells the team what to do after the operation.
• Certain cancers: Breast, rectal and some stomach cancers just do better with chemo leading, because that’s what the evidence keeps showing.

So chemo first isn’t a delay, it’s a plan. Working out the right order for your case is exactly why a second opinion before treatment is worth it.

Other times you just take the tumour out and get on with it. These are those cases.

• It’s clearly removable: When the tumour is contained and operable as it stands, there’s no real reason to wait, so surgery goes first.
• You need the full pathology: Removing it first gives the complete read on type and grade, and that shapes whatever chemo follows.
• Chemo won’t help yet: Some cancers simply don’t shrink with chemo, so holding back surgery for it would gain nothing.
• It can’t wait: A tumour blocking, bleeding or pressing on something usually has to come out first, whatever the long game looks like.

So surgery first is about acting when waiting buys you nothing. In the right cases, robotic cancer surgery takes the tumour out precisely and gets recovery moving sooner.

Dr. Sandeep Nayak brings 24 years of surgical oncology experience, DNB qualifications in Surgical Oncology and General Surgery and a fellowship in Laparoscopic and Robotic Onco-Surgery to every treatment decision across all cancer types. He weighs the order of treatment on the evidence and your specific case, rather than defaulting to whichever step is quickest.

That careful sequencing is what gives a treatment plan its best chance. Every case at MACS Clinic goes through a full tumour board, where surgery, chemotherapy and radiation are weighed together before the order is set. Call +91 8104310753 to book your consultation.

References:

1. National Cancer Institute — Types of Cancer Treatment. https://www.cancer.gov/
2. World Health Organisation — Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer